title: Increased anandamide uptake by sensory neurons contributes to hyperalgesia in a model of cancer pain.
abstract: Opioids do not effectively manage pain in many patients with advanced cancer. Because anandamide (AEA) activation of cannabinoid type-1 receptors (CB1R) on nociceptors reduces nociception, manipulation of AEA metabolism in the periphery may be an effective alternative or adjuvant therapy in the management of cancer pain. AEA is hydrolyzed by the intracellular enzyme fatty acid amide hydrolase (FAAH), and this enzyme activity contributes to uptake of AEA into neurons and to reduction of AEA available to activate CB1R. We used an in vitro preparation of adult murine dorsal root ganglion (DRG) neurons co-cultured with fibrosarcoma cells to investigate how tumors alter the uptake of AEA into neurons. Evidence that the uptake of [(3)H]AEA into dissociated DRG cells in the co-culture model mimicked the increase in uptake that occurred in DRG cells from tumor-bearing mice supported the utility of the in vitro model to study AEA uptake. Results with the fluorescent AEA analog CAY10455 confirmed that an increase in uptake in the co-culture model occurred in neurons. One factor that contributed to the increase in [(3)H]AEA uptake was an increase in total cellular cholesterol in the cancer condition. Treatment with the FAAH inhibitor URB597 reduced CAY10455 uptake in the co-culture model to the level observed in DRG neurons maintained in the control condition (i.e., in the absence of fibrosarcoma cells), and this effect was paralleled by OMDM-1, an inhibitor of AEA uptake, at a concentration that had no effect on FAAH activity. Maximally effective concentrations of the two drugs together produced a greater reduction than was observed with each drug alone. Treatment with BMS309403, which competes for AEA binding to fatty acid binding protein-5, mimicked the effect of OMDM-1 in vitro. Local injection of OMDM-1 reduced hyperalgesia in vivo in mice with unilateral tumors in and around the calcaneous bone. Intraplantar injection of OMDM-1 (5μg) into the tumor-bearing paw reduced mechanical hyperalgesia through a CB1R-dependent mechanism and also reduced a spontaneous nocifensive behavior. The same dose reduced withdrawal responses evoked by suprathreshold mechanical stimuli in naive mice. These data support the conclusion that OMDM-1 inhibits AEA uptake by a mechanism that is independent of inhibition of FAAH and provide a rationale for the development of peripherally restricted drugs that decrease AEA uptake for the management of cancer pain.
authors: Department of Diagnostic and Biological Sciences, Dental School, University of Minnesota, Minneapolis, MN, USA.
authors: Iryna A
authors: IA
authors: Khasabova
authors: Michelle
authors: M
authors: Holman
authors: Tim
authors: T
authors: Morse
authors: Natalya
authors: N
authors: Burlakova
authors: Lia
authors: L
authors: Coicou
authors: Catherine
authors: C
authors: Harding-Rose
authors: Don A
authors: DA
authors: Simone
authors: Virginia S
authors: VS
authors: Seybold
mesh_terms: D000818:Animals; D001095:Arachidonic Acids / Q000378:metabolism*; D001549:Benzamides / Q000494:pharmacology; D001932:Brain Neoplasms / Q000150:complications / Q000473:pathology; D063387:Cannabinoid Receptor Antagonists / Q000494:pharmacology; D002219:Carbamates / Q000494:pharmacology; D002478:Cells, Cultured; D018920:Coculture Techniques; D004195:Disease Models, Animal; D063388:Endocannabinoids / Q000378:metabolism*; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005354:Fibrosarcoma / Q000150:complications / Q000473:pathology; D005456:Fluorescent Dyes; D005727:Ganglia, Spinal / Q000166:cytology; D006930:Hyperalgesia / Q000209:etiology*; D007211:Indoles / Q000494:pharmacology; D007783:Lactones; D008297:Male; D051379:Mice; D008809:Mice, Inbred C3H; D010146:Pain / Q000150:complications* / Q000209:etiology / Q000473:pathology*; D017288:Pain Threshold / Q000187:drug effects / Q000502:physiology*; D053284:Polyunsaturated Alkamides / Q000378:metabolism*; D011984:Sensory Receptor Cells / Q000187:drug effects / Q000378:metabolism*; D018709:Statistics, Nonparametric; D014316:Tritium / Q000378:metabolism
chemical_list: D001095:Arachidonic Acids; D001549:Benzamides; D063387:Cannabinoid Receptor Antagonists; D002219:Carbamates; D063388:Endocannabinoids; D004791:Enzyme Inhibitors; D005456:Fluorescent Dyes; D007211:Indoles; D007783:Lactones; D053284:Polyunsaturated Alkamides; C406526:SKM 4-45-1; C500528:cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester; D014316:Tritium; C094023:iodopravadoline; C078814:anandamide
keywords: AEA; Anandamide; CAY10455; CB1R; Cancer; DRG; Dorsal root ganglion; FAAH; FABP; Fatty acid amide hyrdolase; Fatty acid binding protein; Hydrolysis; Hyperalgesia; MβC; Neuron; PBS; PPARα; TRPV1; Transport; URB597; Uptake; anandamide; cannabinoid type-1 receptor; dorsal root ganglion; fatty acid amide hydrolase; fatty acid binding protein; i.pl; intraplantar; methyl-β-cyclodextrin; peroxisome proliferator-activated receptor alpha; phosphate buffered saline; transient receptor potential vanilloid-type 1
references: Mol Genet Metab. 2012 Jul;106(3):330-44
references: 22572546
references: Biochem J. 2004 May 15;380(Pt 1):265-72
references: 14969584
references: Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):4269-74
references: 12655057
references: Pain. 2005 May;115(1-2):95-106
references: 15836973
references: CNS Drug Rev. 2006 Spring;12(1):21-38
references: 16834756
references: PLoS One. 2009;4(3):e4989
references: 19330032
references: Curr Mol Med. 2002 Aug;2(5):485-505
references: 12125814
references: J Pharmacol Exp Ther. 2002 Jul;302(1):73-9
references: 12065702
references: Br J Pharmacol. 2006 Feb;147(3):281-8
references: 16331291
references: J Neurosci. 2001 Dec 1;21(23):9367-76
references: 11717370
references: Biochem Pharmacol. 2003 May 1;65(9):1473-81
references: 12732359
references: Eur J Pharmacol. 2004 May 10;492(1):1-11
references: 15145699
references: Br J Pharmacol. 2009 Feb;156(3):412-9
references: 19226258
references: J Biol Chem. 2012 Oct 5;287(41):34660-82
references: 22879589
references: J Neurophysiol. 2008 Nov;100(5):2794-806
references: 18784270
references: J Biol Chem. 2005 Apr 1;280(13):12212-20
references: 15657045
references: J Biol Chem. 2012 Jan 27;287(5):3415-24
references: 22170058
references: Eur J Neurosci. 2006 Jul;24(1):1-6
references: 16800863
references: J Pharmacol Exp Ther. 2000 Apr;293(1):289-95
references: 10734181
references: J Neurosci. 2008 Oct 29;28(44):11141-52
references: 18971457
references: J Orthop Res. 1996 Jan;14(1):2-6
references: 8618161
references: Science. 1997 Aug 22;277(5329):1094-7
references: 9262477
references: J Neurosci. 2007 Sep 19;27(38):10289-98
references: 17881535
references: J Neurosci. 2009 Apr 8;29(14):4640-51
references: 19357288
references: Chem Biol. 2009 Jun 26;16(6):624-32
references: 19481477
references: Hepatology. 2003 Nov;38(5):1167-77
references: 14578855
references: Cell Mol Life Sci. 2005 Feb;62(3):386-95
references: 15723173
references: Pharmacol Biochem Behav. 2011 Oct;99(4):718-25
references: 21740924
references: Nature. 1996 Nov 7;384(6604):83-7
references: 8900284
references: J Biol Chem. 2010 Oct 22;285(43):32679-32683
references: 20716527
references: J Neurosci Res. 2005 Jul 15;81(2):275-83
references: 15920744
references: Cancer. 2002 Feb 1;94(3):832-9
references: 11857319
references: Biochemistry. 2004 Jun 29;43(25):8184-90
references: 15209515
references: Neuropharmacology. 2008 Mar;54(3):521-9
references: 18093621
references: Pain. 2006 Dec 15;126(1-3):102-14
references: 16844297
references: Pharmacol Res. 2011 Jul;64(1):60-7
references: 21440630
references: J Neurosci. 2006 Jan 25;26(4):1281-92
references: 16436616
references: J Pharmacol Exp Ther. 2009 Sep;330(3):902-10
references: 19502530
references: J Neurosci. 2001 Dec 1;21(23):9355-66
references: 11717369
references: Trends Biochem Sci. 2010 Nov;35(11):601-8
references: 20570522
references: Nat Neurosci. 2007 Jul;10(7):870-9
references: 17558404
references: Nat Neurosci. 2011 Nov 20;15(1):64-9
references: 22101642
references: CNS Neurol Disord Drug Targets. 2009 Dec;8(6):403-21
references: 19839937
references: Eur J Pharmacol. 2007 Jul 2;566(1-3):117-9
references: 17434479
references: Nature. 1994 Dec 15;372(6507):686-91
references: 7990962
references: Neuropharmacology. 2008 Jul;55(1):85-93
references: 18534634
references: Br J Pharmacol. 2011 Aug;163(7):1379-90
references: 21323908
references: Br J Pharmacol. 2008 Dec;155(8):1297-306
references: 18724387
references: PLoS One. 2012;7(8):e40079
references: 22870192
references: Pain. 2012 Sep;153(9):1837-1846
references: 22727500
references: Anesthesiology. 2009 Jul;111(1):173-86
references: 19512863
references: J Biol Chem. 1995 Jul 21;270(29):17250-6
references: 7615524
references: ACS Chem Neurosci. 2012 May 16;3(5):364-8
references: 22860204
references: Clin Exp Pharmacol Physiol. 2007 Nov;34(11):1186-90
references: 17880375
references: Neuroscience. 2000;98(3):585-98
references: 10869852
references: J Neurophysiol. 2001 Aug;86(2):629-40
references: 11495938
references: Pain. 2008 May;136(1-2):188-201
references: 18316160
references: Pain. 1988 Apr;33(1):87-107
references: 2837713
references: Trends Pharmacol Sci. 2012 Apr;33(4):181-5
references: 22297258
references: J Pharmacol Exp Ther. 2006 Jun;317(3):1365-71
references: 16510698
references: J Neurosci. 2012 Sep 12;32(37):12735-43
references: 22972997
references: Cytometry. 1984 Jan;5(1):42-54
references: 6199166
references: Proc Natl Acad Sci U S A. 2009 Apr 14;106(15):6375-80
references: 19307565
references: Brain Res. 1992 Apr 3;576(2):254-62
references: 1325239
references: J Biol Chem. 2001 Mar 9;276(10):6967-73
references: 11118429
references: Pharmacol Res. 2010 Sep;62(3):249-58
references: 20416378
references: Proc Natl Acad Sci U S A. 2004 Jun 8;101(23):8756-61
references: 15138300
references: Neuroscientist. 2012 Feb;18(1):70-81
references: 21518816
references: Brain Res Bull. 2010 Apr 29;82(1-2):7-17
references: 20206240